Jeffrey S. Parkin

Array ( [id] => 13035415 [patent_doc_number] => 10039820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => West nile virus vaccine comprising WN-80E recombinant subunit protein [patent_app_type] => utility [patent_app_number] => 15/331596 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8031 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393939 [patent_doc_number] => 20170014474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'SCREENING METHOD FOR THE IDENTIFICATION OF AGENTS CAPABLE OF ACTIVATING CD4+CD25+ REGULATORY T-CELLS THROUGH INTERACTIONS WITH THE HIV-1 GP120 BINDING SITE ON CD4' [patent_app_type] => utility [patent_app_number] => 15/285561 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17630 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929103 [patent_doc_number] => 20190048067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => HIV ANTIBODY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/762442 [patent_app_country] => US [patent_app_date] => 2016-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13672791 [patent_doc_number] => 20160375129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES [patent_app_type] => utility [patent_app_number] => 15/264926 [patent_app_country] => US [patent_app_date] => 2016-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15264926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15073501 [patent_doc_number] => 10466231 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Variant angola marburg virus [patent_app_type] => utility [patent_app_number] => 15/261608 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 92 [patent_no_of_words] => 21765 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15261608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588511 [patent_doc_number] => 20170112922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINE' [patent_app_type] => utility [patent_app_number] => 15/251758 [patent_app_country] => US [patent_app_date] => 2016-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 17495 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15251758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11857930 [patent_doc_number] => 09737597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-22 [patent_title] => 'Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins' [patent_app_type] => utility [patent_app_number] => 15/251684 [patent_app_country] => US [patent_app_date] => 2016-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 109 [patent_no_of_words] => 17492 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15251684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844578 [patent_doc_number] => 09732122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins' [patent_app_type] => utility [patent_app_number] => 15/251207 [patent_app_country] => US [patent_app_date] => 2016-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 109 [patent_no_of_words] => 17492 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15251207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11499190 [patent_doc_number] => 20170073376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'VIRAL INHIBITORY NUCLEOTIDE SEQUENCES AND VACCINES' [patent_app_type] => utility [patent_app_number] => 15/228451 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17864 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16831029 [patent_doc_number] => 11007260 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Infectious disease vaccines [patent_app_type] => utility [patent_app_number] => 15/746286 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 107 [patent_no_of_words] => 70951 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120653 [patent_doc_number] => 20160317628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/214817 [patent_app_country] => US [patent_app_date] => 2016-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 19360 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15214817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114916 [patent_doc_number] => 20160311890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'Therapeutic and Diagnostic Methods Using TIM-3' [patent_app_type] => utility [patent_app_number] => 15/208924 [patent_app_country] => US [patent_app_date] => 2016-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 23785 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15208924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604090 [patent_doc_number] => 20170121391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'POTENT GLYCOPROTEIN ANTIBODY AS A THERAPEUTIC AGAINST EBOLA VIRUS' [patent_app_type] => utility [patent_app_number] => 15/204381 [patent_app_country] => US [patent_app_date] => 2016-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 19791 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15204381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18186407 [patent_doc_number] => 11576965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens [patent_app_type] => utility [patent_app_number] => 15/741443 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 41 [patent_no_of_words] => 20492 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15741443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11567436 [patent_doc_number] => 20170106080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'LIPOSOME-PEPTIDE CONJUGATE AND METHOD OF USING SAME TO INDUCE PRODUCTION OF ANTI-HIV ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/195841 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 8982 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862375 [patent_doc_number] => 20180179299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => TRI-SPECIFIC ANTIBODIES FOR HIV THERAPY [patent_app_type] => utility [patent_app_number] => 15/579280 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421344 [patent_doc_number] => 20170029489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/170838 [patent_app_country] => US [patent_app_date] => 2016-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 17479 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15170838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16549754 [patent_doc_number] => 10882903 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Methods and compositions for treating an alphavirus infection [patent_app_type] => utility [patent_app_number] => 15/574351 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 16820 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15574351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067690 [patent_doc_number] => 20160264649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/152630 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 114212 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15152630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129259 [patent_doc_number] => 20160326234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS' [patent_app_type] => utility [patent_app_number] => 15/146990 [patent_app_country] => US [patent_app_date] => 2016-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27726 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15146990 [rel_patent_id] =>[rel_patent_doc_number] =>)